Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 1/20 | 0.59 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.56 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.56 |
| ▸ | CTNNB1 | P35222 | 7/20 | 0.55 |
| ▸ | WNT3A | P56704 | 7/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29696055 | 0.98 | HTR1B (0.57) | HTR1BTAS1R3TAS1R1CTNNB1WNT3A | |
| SCHEMBL3641214 | 0.86 | HTR1B (0.59) | HTR1BTAS1R3TAS1R1CA12CA1 | |
| SCHEMBL29707696 | 0.83 | HTR1B (0.56) | HTR1BTAS1R3TAS1R1CTNNB1WNT3A | |
| SCHEMBL6824879 | 0.82 | CTNNB1 (0.58) | HTR1BTAS1R3TAS1R1CTNNB1WNT3A | |
| SCHEMBL13516717 | 0.81 | CTNNB1 (0.61) | HTR1BTAS1R3TAS1R1CTNNB1WNT3A | |
| SCHEMBL30791009 | 0.81 | CTNNB1 (0.61) | HTR1BTAS1R3TAS1R1CTNNB1WNT3A | |
| SCHEMBL103953 | 0.80 | CTNNB1 (0.59) | HTR1BTAS1R3TAS1R1CTNNB1WNT3A | |
| SCHEMBL28431104 | 0.80 | CTNNB1 (0.59) | HTR1BTAS1R3TAS1R1CTNNB1WNT3A | |
| SCHEMBL12020481 | 0.79 | HTR1B (0.63) | HTR1BTAS1R3TAS1R1CTNNB1WNT3A | |
| SCHEMBL22819676 | 0.79 | CTNNB1 (0.52) | HTR1BTAS1R3TAS1R1CTNNB1WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113122060-A | Preparation method of ink and quantum dot film | TCL集团股份有限公司 | 2021-07-16 | — | — | CN | claimed |
| CN-106928241-A | A kind of methoxycarbonyl group benzo furans simultaneously [2,3 d] pyrimidines and preparation and application of 4 substituted amido 6 | 中山大学 | 2017-07-07 | — | — | CN | claimed |
| US-20250179055-A1 | Substituted 2-(pyrrolidine-3-yl)acetic acid derivative, preparation method and use thereof | INNOVSTONE THERAPEUTICS LIMITED (CN) | 2025-06-05 | — | — | US | disclosed |
| WO-2025103442-A1 | SUBSTITUTED 2-(PYRROLIDIN-3-YL)ACETIC ACID DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊石医药科技有限公司 | 2025-05-22 | — | — | WO | disclosed |
| WO-2024188287-A1 | BRM INHIBITOR AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 贝达药业股份有限公司 | 2024-09-19 | — | — | WO | disclosed |
| CN-109069514-B | Antibacterial compound and application thereof | 结核病药物开发全球联盟公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-114728925-B | Amine derivative serving as SSAO/VAP-1 inhibitor and application thereof | 广东东阳光药业股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-112272553-B | Substituted benzofurans, benzopyrroles, benzothiophenes and structurally related complement inhibitors | 拜奥克里斯特制药公司 | 2023-09-22 | — | — | CN | disclosed |
| EP-4148053-A1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | The Global Alliance for TB Drug Development, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| EP-3426255-B1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2022-11-30 | — | — | EP | disclosed |
| EP-3426255-B1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2022-11-30 | — | — | EP | disclosed |
| WO-2004039366-A1 | NICOTINIC ACETYLCHOLINE AGONISTS IN THE TREATMENT OF GLAUCOMA AND RETINAL NEUROPATHY | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-05-13 | — | — | WO | disclosed |
| US-20030232853-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-18 | — | — | US | disclosed |
| WO-2003070731-A2 | AZABICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2003-08-28 | — | — | WO | disclosed |
| US-20030105089-A1 | Substituted 7-aza[2.2.1]bicycloheptanes for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-06-05 | — | — | US | disclosed |
| WO-2003022856-A1 | SUBSTITUTED 7-AZA[2.2.1] BICYCLOHEPTANES FOR THE TREATMENT OF DISEASES | PHARMACIA & UPJOHN COMPANY (US) | 2003-03-20 | — | — | WO | disclosed |
| US-20020099212-A1 | For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-07-25 | — | — | US | disclosed |
| US-6348474-B1 | COMPOUNDS AS ANTIDIABETIC AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-19 | — | — | US | disclosed |
| EP-0995742-A1 | SULFONAMIDE COMPOUNDS AND MEDICINAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-26 | — | — | EP | disclosed |
| US-4734407-A | ANIMAL GROWTH REGULATORS | BAYER AKTIENGESELLSCHAFT (DE) | 1988-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232853-A1 | Azabicyclic compounds for the treatment of disease | TPMT, MALT1, AZI2 | HTR1B 2111/4885TAS1R3 4582/4885TAS1R1 3626/4885 |
| US-20020099212-A1 | For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity | PDE2A, PDE3A, PDE12 | HTR1B 200/4885TAS1R3 1485/4885TAS1R1 1188/4885 |
| US-20030105089-A1 | Substituted 7-aza[2.2.1]bicycloheptanes for the treatment of disease | CHRNA7, CHRNA1, CHRNA6 | HTR1B 293/4885TAS1R3 2769/4885TAS1R1 1954/4885 |
| US-20250179055-A1 | Substituted 2-(pyrrolidine-3-yl)acetic acid derivative, preparation method and use thereof | PCSK9, LPL, LYPLA1 | HTR1B 3483/4885TAS1R3 4748/4885TAS1R1 4593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.